CVI Holdings’s Cardiff Oncology CRDF Stock Holding History

CVI Holdings’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-51,241	Closed	-$237K	–	44
2018 Q2	$237K	Buy	+51,241	New	+$857K	0.3%	29

Other funds holding CRDF

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SNB

Security National Bank Omaha, Nebraska $838M AUM 39.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CVI Holdings's CRDF Position: Q3 2018 in Review

CVI Holdings sold out of Cardiff Oncology (CRDF) in Q3 2018, closing a stake of 51,241 shares — an estimated $237K sold.

CVI Holdings first reported a position in CRDF in Q2 2018 and held it in 1 quarter. The position peaked at $237K in Q2 2018. 33 funds tracked by Wall St. Rank hold CRDF as of Q3 2018.

CVI Holdings reported no remaining Cardiff Oncology position as of Q3 2018 after selling out during the quarter.
CVI Holdings sold 51,241 Cardiff Oncology shares in Q3 2018, an estimated $237K.
CVI Holdings first reported a position in Cardiff Oncology in Q2 2018 and held it in 1 quarter.
CVI Holdings's Cardiff Oncology position peaked at $237K in Q2 2018.
33 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2018.

Based on CVI Holdings's 13F filing for Q3 2018, filed 14 Nov 2018.